H. Lundbeck A/S (HLUN A)

H. Lundbeck is a Danish pharmaceutical company focused almost entirely on brain diseases—psychiatry and neurology. It develops and markets treatments for conditions such as depression, schizophrenia, Alzheimer’s disease, and migraine, among other CNS disorders. Specialization in central nervous system therapies, rather than a broad primary-care portfolio, is its defining characteristic.

Market

Copenhagen

Sector

Healthcare

Trend

Strong uptrend

Last close

43.85 (-0.23% on the day)

MA50

37.72

MA200

35.53

52-week range

31.65–43.95

Market cap

40.7B DKK

P/E

10.34

Dividend yield

2.78%

Data as of

2026-09-04

All markets — KeepWinning global stock screener

Other companies on Copenhagen: FLSmidth & Co. A/S (FLS), Alm. Brand A/S (ALMB), Zealand Pharma A/S (ZEAL), TORM plc (TRMD A), Royal Unibrew A/S (RBREW), Ambu A/S (AMBU B)